Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb Stock Rises
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.
Business Insider
11h
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers
Squibb
(BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...
The Washington Post
16h
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The new drug, Bristol Myers
Squibb
’s Cobenfy, targets a different area of the brain than traditional antipsychotic drugs to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Promotes watch collection
'Harry Potter' star dies
World's oldest cheese found
Killer gets life sentence
50/50 ball ownership suit
Ending password-sharing
Boxes to distribute Narcan
Producing doc on Diddy
Targeted Black residents?
Urgent safety alert for 737s
Stadiums to serve as shelters
Fake Biden robocalls fine
More executives leave
On Secret Service failures
Chinese submarine sank
NC board removes 747K
NIH finds misconduct
Arrives in Luxembourg
WI duplicate ballot flap
Rose announces retirement
Capital goods orders up
Military recruiting rebounds
RU hits Ukraine's power grid
Feedback